BOEHRINGER INGELHEIM VETMEDICA GMBH Patent applications |
Patent application number | Title | Published |
20160126151 | METHOD FOR PRODUCING A PLURALITY OF MEASUREMENT REGIONS ON A CHIP, AND CHIP WITH MEASUREMENT REGIONS - A a chip and a method for producing the chip with a plurality of measurement regions which are provided with electrodes for electrically detecting reactions in which, in order to reliably separate the individual measurement regions from one another, a monolayer of a fluorosilane is formed on the chip surface which has strongly hydrophobic properties. Therefore, during spotting with a liquid, the drops of liquid applied by spotting can be reliably prevented from coalescing, and thus, causing mixing of the substances in the drops of liquid which are supposed to be immobilized in the measurement regions. | 05-05-2016 |
20160051984 | DEVICE FOR CONTROLLING FLUID FLOWS IN LAB-ON-A-CHIP SYSTEMS - An array of valves are arranged in n columns and m lines and which are each designed to control a fluid flow in an associated flow channel in a lab-on-a-chip system. The array includes at least two valves, every column having not more than one valve and every line having from zero to n valves. A device is used for actuating the valves. The valves are pressure-actuated. To produce the device, the flow channels are arranged in accordance with the arrangement of the valves. Which valves are actuated being changeable by movement of projections relative to array of valves so as to change which valves the projections are pressed against. | 02-25-2016 |
20160047832 | SYSTEM FOR OPERATING A SYSTEM FOR THE INTEGRATED AND AUTOMATED ANALYSIS OF DNA OR PROTEIN - A system for the integrated and automated analysis of DNA or protein, including a single-use cartridge, with an analysis device having a control device, and devices for capturing and processing signals, the control device carrying out a completely automatic process and evaluation of molecular diagnostic analysis via single-use cartridges (Lab-on-a-Chip). Controlling of an analysis process, which occurs in the cartridge, involves the subsequent displacement and thermostatisation of liquids with a first device, and with a second device the signals which are obtained during the analysis are processed. The first and the second devices are synchronized in such a manner that the analysis process of the sample can be carried out in a totally integrated manner thus producing an immediate result. | 02-18-2016 |
20160041193 | METHOD FOR OPERATING A SYSTEM FOR THE INTEGRATED AND AUTOMATED ANALYSIS OF DNA OR PROTEIN - A method for the integrated and automated analysis of DNA or protein, including a single-use cartridge, with an analysis device having a control device, and devices for capturing and processing signals, the control device carrying out a completely automatic process and evaluation of molecular diagnostic analysis via single-use cartridges (Lab-on-a-Chip). Controlling of an analysis process, which occurs in the cartridge, involve the subsequent displacement and thermostatisation of liquids with a first device, and with a second device the signals which are obtained during the analysis are processed. The first and the second devices are synchronized in such a manner that the analysis process of the sample can be carried out in a totally integrated manner thus producing an immediate result. | 02-11-2016 |
20160025667 | APPARATUS FOR THE DETECTION OF LIQUIDS OR SUBSTANCES FROM LIQUIDS - An apparatus for detecting liquids or substances from liquids in spatially separate reaction zones using a plug-in module or a chip card for rapid immunological tests, for example, with the help of a reading device. The liquids or substances from liquids are detected by a sensor array and on which at least one diaphragm is arranged. Individual sensors are spatially separated from each other on a plane by means of walls. The diaphragm is filled with liquid that is to be analyzed. Sealed reaction chambers are created when pressure is applied to the diaphragm. Pores in the diaphragm are completely closed in the zone of the walls while the pores are merely reduced in size and liquid can continue to be exchanged in zones directly above the sensors. No liquid can be exchanged between adjacent reaction chambers as long as pressure is applied to and compresses the diaphragm. | 01-28-2016 |
20150313918 | CICLESONIDE FOR THE TREATMENT OF AIRWAY DISEASE IN HORSES - The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD). | 11-05-2015 |
20150064249 | PHARMACEUTICAL TABLET FORMULATION FOR THE VETERINARY MEDICAL SECTOR, METHOD OF PRODUCTION AND USE THEREOF - The invention is directed to a pharmaceutical tablet formulation for the veterinary medical sector containing an instable ACE inhibitor or a pharmaceutically acceptable salt thereof as a first pharmaceutically active substance, and pimobendan or a pharmaceutically acceptable salt thereof as a second pharmaceutically active substance, comprising granules which contain carrier core particles coated with at least one layer wherein the first pharmaceutically active substance is present, the granules being embedded in a tablet matrix wherein the second pharmaceutically active substance is present. It is provided a “fixed-dose-combination” which allows to ease the treatment and administration of the medication, improves the medication compliance by reducing the pill burden to the animal holder and enables the better observation of and adherence to the therapy by decreasing the number of tablets to be administered. The lower number of tablets leads to a lower treatment failure rate, minimizes dosage mistakes and avoids confusions by false dose intake and slower development of resistance. | 03-05-2015 |
20150053207 | INHALER - An inhaler, preferably for insertion into a nostril, in particular a horse's nostril, with an inhalation valve, which has a movable valve element, whereby the valve element is designed in an annular manner and has an outer edge and an inner edge, whereby the valve element is fastened at the outer edge, the inner edge forms the boundary of an indentation of the valve element, and the inhalation valve has a valve body seat that corresponds to the inner edge. | 02-26-2015 |
20150053202 | INHALER - An inhaler, preferably for insertion into a nostril, in particular a horse's nostril, with a pressure generator, which has a tensioning device for the drive, and with a tensioning mechanism for tensioning the tensioning device, whereby the tensioning mechanism has a lever gear for tensioning the tensioning device. | 02-26-2015 |
20150038441 | KIT-IN-PARTS FOR CLEANING AND TREATING EARS OF COMPANION ANIMALS - The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of otitis externa, application and dosage information, cannules, cotton swabs, gauzes and information about the cleaning and maintenance ears of a companion animal. | 02-05-2015 |
20150025082 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION - The present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising one or more etherified cyclodextrin derivatives; one or more water-soluble preservatives; preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; benzethonium chloride; cetylpyridinium chloride; sodium metabisulfite; sodium acetate; parabenes and salts thereof, preferably methylparabene, ethylparabene, propylparabene, butylparabene, butylparabene sodium; or combinations thereof; and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound, such as pimobendan, in aqueous solution whereby the water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivatives allowing the use in an oral administration form. | 01-22-2015 |
20140370058 | ONE DOSE VACCINATION AGAINST MYCOPLASMA INFECTIONS OF PIGS - The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by | 12-18-2014 |
20140364473 | ORAL SUSPENSION COMPRISING TELMISARTAN - A pharmaceutical solution with a pH value of 10 or higher contains an angiotensin II receptor antagonist, where one or more sugar alcohols are present up to a total concentration of 40 wt. % to 70 wt. %. | 12-11-2014 |
20140363510 | PHARMACEUTICAL COMPOSITION INCLUDING PIMOBENDAN - A solid formulation includes pimobendan or a pharmaceutically acceptable salt thereof, which is homogenously dispersed with a polyvalent acid and a flavor suitable to animals. | 12-11-2014 |
20140332438 | WATER-SOLUBLE MELOXICAM GRANULES - A method of treating animals includes administering water soluble granules to an animal, where the water soluble granules include meloxicam, salt forming agent operable to form a meloxicam salt, a binder, and a carrier. | 11-13-2014 |
20140303096 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS - The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal. | 10-09-2014 |
20140288138 | Angiotensin II Receptor Antagonist for the Prevention or Treatment of Systemic Diseases in Cats - A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan). | 09-25-2014 |
20140255442 | NOVEL EUROPEAN PRRSV STRAIN - The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines. | 09-11-2014 |
20140235648 | LIQUID PREPARATION COMPRISING PIMOBENDAN - A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether. | 08-21-2014 |
20140234357 | H5 PROTEINS OF H5N1 INFLUENZA VIRUS FOR USE AS A MEDICAMENT - The present invention is based on the surprising finding that H5 protein of clade 1 H5N1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with H5N1 HA. In one aspect, the invention is thus directed to H5 protein of clade 1 H5N1 virus for use in a method of treating or preventing infections with H5N1 virus of a different clade, wherein the H5N1 virus of a different clade comprises a particular polynucleotide and/or H5 protein. | 08-21-2014 |
20140199337 | INFLUENZA H5 VACCINES - The present invention is based on the surprising finding that H5 protein of clade 1 H5N1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with H5N1 HA. In one aspect, the invention is thus directed to H5 protein of clade 1 H5N1 virus for use in a method of treating or preventing infections with H5N1 virus of a different clade, namely of a clade different from clade 1 or from any clade with the exception of clade 1, respectively. | 07-17-2014 |
20140186394 | METHOD OF MAKING A MYCOPLASMA VACCINE - The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of | 07-03-2014 |
20140186393 | IMMUNOGENIC COMPOSITION COMPRISING MYCOPLASMA ANTIGENS - The present invention relates to an immunogenic composition comprising: a) one or more antigen of | 07-03-2014 |
20140179651 | CICLESONIDE FOR THE TREATMENT OF AIRWAY DISEASE IN HORSES - The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD). | 06-26-2014 |
20140179650 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE - The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof. | 06-26-2014 |
20140179639 | MELOXICAM FOR THE TREATMENT OF RESPIRATORY DISEASES IN PIGS - A method of treating or preventing a respiratory disease in a pig is described that includes administering to the pig in need thereof an effective amount of meloxicam or a pharmaceutically acceptable salt thereof. | 06-26-2014 |
20140171415 | FUNNY CURRENT (IF) INHIBITORS FOR USE IN A METHOD OF TREATING AND PREVENTING HEART DISEASE IN CANINE - The present invention relates to an I | 06-19-2014 |
20140155338 | USE OF PDE III INHIBITORS FOR THE REDUCTION OF HEART SIZE IN MAMMALS SUFFERING FROM HEART FAILURE - A phosphodiesterase type III (PDE III) inhibitor or Ca | 06-05-2014 |
20140135363 | PROTON PUMP INHIBITOR FOR USE IN A METHOD OF TREATING DERMATOLOGICAL DISEASES IN CANINE - The present invention relates to a proton pump inhibitor or a pharmaceutically acceptable salt thereof for the treatment of skin diseases in canine patients. The invention also relates to improving the quality of life, improving the general health condition as well as preventing secondary infections in canine patients suffering from skin diseases. Moreover, the present invention also relates to a pharmaceutical composition for topical administration, preferably for use in a method of treating skin diseases and/or improving the general health condition in canine patients, wherein such pharmaceutical formulation comprises a proton pump inhibitor or a pharmaceutically acceptable salt thereof and one or more excipients. | 05-15-2014 |
20140113893 | Highly Concentrated Stable Meloxicam Solutions for Needleless Injection - An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients. | 04-24-2014 |
20140066440 | Highly Concentrated Stable Meloxicam Solutions for Needleless Injection - A method for treating pain, inflammation, fever and respiratory complaints in mammals comprising administering by needleless injection to a mammal in need of such treatment an aqueous cyclodextrin-free solution of meloxicam containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base. | 03-06-2014 |
20140057022 | POTASSIUM CONTAINING PREPARATION, PROCESS FOR THE PRODUCTION THEREOF AND USE THEREOF - The invention is directed to a potassium containing preparation or potassium bolus for the prevention or treatment of potassium deficit and optionally other deficit of minerals in ruminants, a process for the production thereof as well as the use thereof. The present invention makes it possible to provide a potassium containing preparation or potassium bolus with a high content of up to 70 wt.-% of potassium salt, based on the total weight of the potassium containing preparation, by adding only a relatively small amount of calcium chloride (15 to 40 wt.-%) and water (10 to 22 wt.-%) to the potassium salt. | 02-27-2014 |
20140031540 | CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(SS- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS - The invention relates to a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments. | 01-30-2014 |
20140030290 | Infectious Clones of RNA Viruses and Vaccines and Diagnostic Assays Derived Thereof - An infectious clone based on the genome of a wild-type RNA virus is produced by the process of providing a host cell not susceptible to infection by the wild-type RNA virus, providing a recombinant nucleic acid based on the genome of the wild-type RNA virus, transfecting the host cell with the recombinant nucleic acid and selecting for infectious clones. The recombinant nucleic acid comprises at least one full-length DNA copy or in vitro-transcribed RNA copy or a derivative of either. The infectious clones can be used in single or dual purpose vaccines and in viral vector vaccines. | 01-30-2014 |
20130323277 | SCHMALLENBERG VIRUS (SBV) VACCINE, METHODS OF PRODUCTION, AND USES THEREOF - The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV. | 12-05-2013 |
20130323210 | INFECTIOUS SCHMALLENBERG VIRUS FROM CLONED CDNAS AND USES THEREOF - The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the complete genome of an infectious Schmallenberg virus (SBV) useful for studying viremia and diseases caused by SBV in ruminants, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of viremia and diseases caused by SBV. | 12-05-2013 |
20130230558 | ONE DOSE VACCINATION AGAINST MYCOPLASMA INFECTIONS OF PIGS - The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by | 09-05-2013 |
20130203690 | PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE - Phosphodiesterase type III (PDE III) inhibitor or a “Ca | 08-08-2013 |
20130195977 | Low Concentration Meloxicam Tablets - A solid tablet formed through direct compression of powder, the powder comprising meloxicam as an active ingredient and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the meloxicam. | 08-01-2013 |
20130193028 | WATER-SOLUBLE MELOXICAM GRANULES - Water soluble meloxicam granules include meloxicam, a salt forming agent which forms the meglumine, sodium, potassium, or ammonium salt of meloxicam, a binder, a sugar or sweetener, and a carrier, and a flavoring agent. | 08-01-2013 |
20130190373 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS - A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment. | 07-25-2013 |
20130183337 | KIT FOR THE PREPARATION OF A VACCINATING AGENT - A kit, a method of using it and a process for preparing a vaccine for immunization against the disease Porcine Circovirus Disease and/or Enzootic Pneumonia in pigs are proposed, in which a first container is only partly filled with a first vaccine and a second container is filled with a second vaccine, the second vaccine being transferred into the first container through an adapter device, when a closure device is penetrated for the first and/or only time, and the vaccinating agent is prepared therein, thus making the operation simple, less error-prone and more hygienic, while reducing the materials required. The adapter device has a pair of oppositely facing piercing elements formed of one of needles, hollow, spikes, wedges with at least one through passage extending through both piercing elements, each of the containers being pierced by a respective one of the piercing elements creating a fluid connection between the containers. | 07-18-2013 |
20130178467 | HIGHLY CONCENTRATED STABLE MELOXICAM SOLUTIONS - Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The formulation according to the invention has a shelf-life of up to 24 months or more. | 07-11-2013 |
20130177613 | PACKAGING ASSEMBLY FOR PHARMACEUTICAL COMPOSITION INCLUDING PIMOBENDAN - A packaging assembly or kit includes packaging material containing a solid formulation including pimobendan dispersed in a polyvalent acid. The kit may also include a package leaflet or user instruction including the information concerning use of the solid formulation, for example, via the oral route for the prevention and/or treatment of congestive heart failure in a mammal in need of such prevention or treatment, preferably in a dog, cat or rodent. | 07-11-2013 |
20130161228 | CONTAINERS FOR COMPOSITIONS COMPRISING MELOXICAM - A plastic container containing a pharmaceutical composition comprising benzoic acid or a derivative or a pharmaceutically acceptable salt thereof and a COX-inhibitor of the oxicam-type or a pharmaceutical acceptable salt thereof, wherein the container material selected from one or more members of the group consisting of a homopolymer of polypropylene (PP), a copolymer of polypropylene (PP), a homopolymer of polyethylene terephthalate (PET) and a copolymer of polyethylene terephthalate (PET), and optionally one or more non-polymeric components. | 06-27-2013 |
20130084332 | TASTE MASKED PHARMACEUTICAL COMPOSITION - This application relates to taste masked multi-layered particles an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water-soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them. | 04-04-2013 |
20130040937 | INHIBITORS FOR TREATING AND PREVENTING HEART FAILURE IN FELINES - The present invention relates to an I | 02-14-2013 |
20130039946 | VACCINE COMPRISING AN ATTENUATED PESTIVIRUS - Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein E | 02-14-2013 |
20130035330 | USE OF MELOXICAM FOR THE LONG-TERM TREATMENT OF MUSCULOSKELETAL DISORDERS IN CATS - The invention is directed to the use of a formulation comprising meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats. No negative effects on renal function occur following a treatment from 10 to 20 months or more. | 02-07-2013 |
20130028931 | NOVEL PRRS VIRUS INDUCING TYPE I INTERFERON IN SUSCEPTIBLE CELLS - The present invention relates to the field of attenuated live viruses useful as vaccine or medicament for preventing or treating Porcine Reproductive and Respiratory Syndrome (PRRS) in swine, and is based on the surprising finding of a PRRS virus which is able to induce the interferon type I response of a cell infected by said virus. In one embodiment, the PRRS virus according to the invention is a PRRS virus mutant comprising, in comparison with the genome of a wild type strain, a mutation in the gene encoding the non structural protein 1 (nsp1) of said virus. | 01-31-2013 |
20130005714 | Water-Soluble Meloxicam Granules - Water soluble meloxicam granules comprising:
| 01-03-2013 |
20120213810 | NOVEL EUROPEAN PRRSV STRAIN - The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines. | 08-23-2012 |
20120213741 | COMMERCIAL SCALE PROCESS FOR PRODUCTION OF PRRSV - The present invention describes an efficient commercial scale production method for the preparation of PRRS virus. | 08-23-2012 |
20120201850 | INFECTIOUS BOVINE VIRAL DIARRHEA VIRUS - The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones. | 08-09-2012 |
20120195927 | GM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS - The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements. | 08-02-2012 |
20120189659 | ATTENUATED PESTIVIRUSES - This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein E | 07-26-2012 |
20120148640 | Pharmaceutical Composition Comprising Pimobendan - The invention relates to novel solid formulations comprising as pharmaceutically active compound pimobendan and to processes for producing such solid formulations. The invention furthermore relates to a method for manufacturing a medicament for the prevention and/or treatment of congestive heart failure, wherein the solid formulations according to the invention are used. | 06-14-2012 |
20120103326 | INHALER - An inhaler for the propellant-free nebulization of a medicament preparation produces a low speed aerosol. The inhaler is combined with an add-on device for intermediate storage of the aerosol produced. The inhaler has a tensioning device for the one-handed tensioning of a drive spring and release thereof. The inhaler is provided with a dispensing device for large animals. | 05-03-2012 |
20120095069 | PHARMACEUTICAL ORAL TELMISARTAN SOLUTION - A pharmaceutical solution, preferably a drinkable pharmaceutical solution of the active substance telmisartan is described, having a pH above 10 and additionally containing one or more sugar alcohols added to improve the flavour and shelf life, wherein the sugar alcohols or the pharmaceutical solution have a maximum content of 1000 ppm of reducing sugars. | 04-19-2012 |
20110293661 | VACCINE STRAINS OF BRACHYSPIRA HYODYSENTERIAE - The present invention relates generally to vaccine strains of | 12-01-2011 |
20110275618 | NOVEL LOW CONCENTRATION MELOXICAM TABLETS - The invention relates to a solid tablet that is directly-compressed of powder, comprising meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam. | 11-10-2011 |
20110275149 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 11-10-2011 |
20110275148 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 11-10-2011 |
20110275147 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 11-10-2011 |
20110251208 | PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY - The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca | 10-13-2011 |
20110243991 | PROCESS FOR PRODUCTION OF VACCINES - The invention relates to a process for the production of a vaccine against bacterial pathogens which produce an AB toxin, like | 10-06-2011 |
20110237532 | 1-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-- PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL - The present invention provides a pharmaceutical composition comprising 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs. The invention further provides respective uses of such compositions and of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or pharmaceutically acceptable forms thereof. | 09-29-2011 |
20110218191 | USE OF MELOXICAM FOR THE LONG TERM-TREATMENT OF KIDNEY DISORDERS IN CATS - The invention is directed to a formulation containing NSAIDs or a pharmacologically acceptable salt thereof of and one or more vehicles for the treatment of kidney diseases in cats. Serum creatinine concentrations increase less over time following treatment with NSAID compared to untreated cats. | 09-08-2011 |
20110201790 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
20110201789 | ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
20110201788 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
20110201787 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
20110201786 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
20110117126 | ATTENUATED PESTIVIRUS - The present invention relates to recombinant attenuated pestiviruses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric E | 05-19-2011 |
20110083985 | CONTAINERS FOR COMPOSITIONS COMPRISING MELOXICAM - A plastic container containing a pharmaceutical composition comprising benzoic acid or a derivative or a pharmaceutically acceptable salt thereof and a COX-inhibitor of the oxicam-type or a pharmaceutical acceptable salt thereof, wherein the container material selected from one or more members of the group consisting of a homopolymer of polypropylene (PP), a copolymer of polypropylene (PP), a homopolymer of polyethylene terephthalate (PET) and a copolymer of polyethylene terephthalate (PET), and optionally one or more non-polymeric components. | 04-14-2011 |
20110033870 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 02-10-2011 |
20100190805 | PREPARATION FOR THE TREATMENT OF EQUINE LAMINITIS - Disclosed is the use of active substances known from human medicine for treating gout in order to pharmaceutically treat equine laminitis, especially the use of a preparation containing at least allopurinol and/or hydrocortisone and/or powdered opium and/or prednisolone and/or prednisone. | 07-29-2010 |
20100035889 | Use of PDE III Inhibitors For The Treatment of Asymptomatic (Occult) Heart Failure - The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca | 02-11-2010 |
20090162396 | gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS - The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements. | 06-25-2009 |
20090082282 | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure - The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca | 03-26-2009 |
20080280840 | MELOXICAM FOR THE TREATMENT OF RESPIRATORY DISEASES IN PIGS - A method of treating or preventing a respiratory disease in a pig, the method comprising administering to the pig in need thereof an effective amount of meloxicam or a pharmaceutically acceptable salt thereof. | 11-13-2008 |
20080207629 | LIQUID PREPARATION COMPRISING PIMOBENDAN - The invention relates to novel liquid preparation comprising a substituted benzimidazol, preferably pimobendan as pharmaceutically active compound. In particular, the present invention relates to liquid preparation comprising an etherified cyclodextrin derivative, preferably in a concentration of about 20 to 70% (w/v) and said substituted benzimidazol, preferably in a concentration of about 0.005 to 0.15% (w/w). | 08-28-2008 |